One size does not fit all when it comes to diabetes management. Integrative medicine seeks to create individualized treatment options – addressing the “whole person” including examining lifestyle patterns as well as medical needs. Dr. Steven Edelman talks with cardiologist Dr. Mimi Guarneri, founder and director of Scripps Center for Integrative Medicine, and patient Ron Bamberger who finds this approach the best way to manage his diabetes. Series: “Taking Control of Your Diabetes (TCOYD)” [9/2011] [Health and Medicine] [Show ID: 20827]

Windows Media Video produced by Minoru Oishi

Duration : 0:2:39

http://pcp.onlinemindanao.com

Type 2 diabetes mellitus today is a global epidemic, a continuing challenge despite the availability of effective therapeutic agents. Current treatment guidelines emphasize early and aggressive treatment targetting the known pathophysiological defects in type 2 diabetes. Yet the reality in clinical practice shows that fewer than 50% of patients under treatment achieve HbA1c levels even in developed countries.
More recently, the addition of incretin-based therapy offers significant solutions to the progressive loss of pancreatic beta cell function and other unmet needs in effective diabetes management. In this session, the role of diminished incretin effects in the metabolic derangements in type 2 diabetes will be reviewed. The mechanism of actions and the therapeutic uses of both incretin enhancers and incretin mimetics will be discussed, highlighting efficacy and safety data since they have been available for use in clinical practice. The role of these agents in addressing earliest defects in glucose homeostasis and postprandial hyperglycemia implies potential of preservation of beta cell function. Incretin-based therapy should clearly be considered as a major part of effective diabetes management in current clinical practice.

Duration : 0:7:9

visit http://www.urdumednotes.com and see more free medical notes in urdu, you can request on for free

Duration : 0:2:21

Part 3 / 5. Interview with Dr Neil Barnard from PCRM on how veganism can reverse and halt diabetes Type II.

Part 1 / 5

http://www.youtube.com/watch?v=PRRYZ1Ffgko

Part 2 of 5

http://www.youtube.com/watch?v=us0BqPtGLm0

Part 4 / 5

http://www.youtube.com/watch?v=QZqX9wuV2Uw

Part 5 of 5

http://www.youtube.com/watch?v=HiIab6jBBOQ

Listen to this excellent podcast interview of Dr Neil Barnard about all the great benefits of adopting a plant based diet. It also focuses also on how one can reverse diabetes Type II by adopting a plant based vegan diet. You just click on this, http://www.abc.net.au/classic/throsby/ then go down to Wednesday Dec 3rd at 10.05am Dr. Neal Barnard, then click on one of 3 choices of Real Player | Windows Media | mp3 download .

Duration : 0:7:12

Type 2 diabetics usually require medication to regulate the disease. But the plethora of choices can be overwhelming!Watch More Health Videos at Health Guru: http://www.healthguru.com/?YT

Duration : 0:2:57

http://www.pcp.onlinemindanao.com

http://www.PhilippinesDailyPhotos.com

http://www.JourneyPhilippines.net

http://www.CagayandeOroBlog.com

Type 2 diabetes mellitus today is a global epidemic, a continuing challenge despite the availability of effective therapeutic agents. Current treatment guidelines emphasize early and aggressive treatment targetting the known pathophysiological defects in type 2 diabetes. Yet the reality in clinical practice shows that fewer than 50% of patients under treatment achieve HbA1c levels even in developed countries.

More recently, the addition of incretin-based therapy offers significant solutions to the progressive loss of pancreatic beta cell function and other unmet needs in effective diabetes management. In this session, the role of diminished incretin effects in the metabolic derangements in type 2 diabetes will be reviewed. The mechanism of actions and the therapeutic uses of both incretin enhancers and incretin mimetics will be discussed, highlighting efficacy and safety data since they have been available for use in clinical practice. The role of these agents in addressing earliest defects in glucose homeostasis and postprandial hyperglycemia implies potential of preservation of beta cell function. Incretin-based therapy should clearly be considered as a major part of effective diabetes management in current clinical practice.

Duration : 0:6:45

Part 1 of 5. Interview with Dr Neil Barnard from PCRM on how veganism can reverse and halt diabetes Type II.

Part 2 of 5

http://www.youtube.com/watch?v=us0BqPtGLm0

Pt 3 / 5

http://www.youtube.com/watch?v=9PZx62ZYPOw

Part 4 of 5

http://www.youtube.com/watch?v=QZqX9wuV2Uw

Part 5 of 5

http://www.youtube.com/watch?v=RB_DLQDfXio

Listen to this excellent podcast interview of Dr Neil Barnard about all the great benefits of adopting a plant based diet. It also focuses also on how one can reverse diabetes Type II by adopting a plant based vegan diet. You just click on this, http://www.abc.net.au/classic/throsby/ then go down to Wednesday Dec 3rd at 10.05am Dr. Neal Barnard, then click on one of 3 choices of Real Player | Windows Media | mp3 download .

Duration : 0:9:12

Type 2 Diabetes is an Animation video by Focus Medica Pte. Ltd that runs for 12.43 mins. For more details visit www.focusmedica.com or write sales@focusmedica.com

Duration : 0:0:57

http://pcp.onlinemindanao.com

Type 2 diabetes mellitus today is a global epidemic, a continuing challenge despite the availability of effective therapeutic agents. Current treatment guidelines emphasize early and aggressive treatment targetting the known pathophysiological defects in type 2 diabetes. Yet the reality in clinical practice shows that fewer than 50% of patients under treatment achieve HbA1c levels even in developed countries.
More recently, the addition of incretin-based therapy offers significant solutions to the progressive loss of pancreatic beta cell function and other unmet needs in effective diabetes management. In this session, the role of diminished incretin effects in the metabolic derangements in type 2 diabetes will be reviewed. The mechanism of actions and the therapeutic uses of both incretin enhancers and incretin mimetics will be discussed, highlighting efficacy and safety data since they have been available for use in clinical practice. The role of these agents in addressing earliest defects in glucose homeostasis and postprandial hyperglycemia implies potential of preservation of beta cell function. Incretin-based therapy should clearly be considered as a major part of effective diabetes management in current clinical practice.

Duration : 0:7:11